Replies to post #15801 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

are you still holding to your contention of an "at risk" launch?

Yes, if TEVA has not obtained an injunction when the Hatch-Waxman stay expires in Feb 2017. (Provided, of course, that NVS/MNTA have received FDA approval for 40mg Copaxone.)